Actively Recruiting

Phase Not Applicable
Age: 18Years - 100Years
FEMALE
NCT05713435

Use of Fractional CO2 Laser Versus Erbium:YAG Laser for the Treatment of GSM in Patients Using Aromatase Inhibitors

Led by Universitaire Ziekenhuizen KU Leuven · Updated on 2024-07-01

162

Participants Needed

1

Research Sites

152 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

To study the efficacy and safety of intravaginal CO2 laser versus intravaginal Er:YAG laser and sham application in alleviating genitourinary symptoms in patients receiving an aromatase inhibitor as adjuvant treatment of breast cancer

CONDITIONS

Official Title

Use of Fractional CO2 Laser Versus Erbium:YAG Laser for the Treatment of GSM in Patients Using Aromatase Inhibitors

Who Can Participate

Age: 18Years - 100Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • History of breast cancer
  • Premenopausal at breast cancer diagnosis
  • Currently using aromatase inhibitors as adjuvant treatment
  • Moderate to severe genitourinary syndrome of menopause symptoms (VAS 64 4/10)
  • Currently menopausal due to biochemical, surgical, or medicinal causes (including GnRH analogues during the trial)
Not Eligible

You will not qualify if you...

  • Not willing to abstain from vaginal intercourse for 1 week after laser therapy
  • Use of non-hormonal vaginal products within 6 weeks before joining
  • Use of hormonal therapy (systemic or local) within 6 months before joining
  • Presence of acute urinary or genital infections
  • History of genital fistula, thin rectovaginal septum, or severe vaginal laceration
  • Pelvic organ prolapse grade 2 or higher
  • Previous vaginal mesh implantation
  • Abnormal cervical smear within 36 months before joining
  • Ongoing or planned active cancer treatment before primary outcome assessment
  • Vaginal stenosis preventing laser probe placement
  • Any condition interfering with study compliance

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

UZ Leuven

Leuven, Flemish Brabant, Belgium, 3000

Actively Recruiting

Loading map...

Research Team

S

Susanne Housmans, MD

CONTACT

J

Jan Deprest, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here